<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955574</url>
  </required_header>
  <id_info>
    <org_study_id>JW-001</org_study_id>
    <nct_id>NCT04955574</nct_id>
  </id_info>
  <brief_title>Probiotic and Antibiotic Therapies in Women With Unexplained Infertility</brief_title>
  <official_title>Probiotic and Antibiotic Therapies in Women With Unexplained Infertility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>One Fertility</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed as a proof of concept pilot study with 3 study arms to evaluate the&#xD;
      safety and feasibility of the use of oral probiotics and/or antibiotics in women with&#xD;
      unexplained infertility/endometriosis. Our secondary outcomes will assess In Vitro&#xD;
      Fertilization outcomes, and changes in the uterine microbiota (bacteria), intestinal barrier&#xD;
      integrity, and urinary metabolites in response to study interventions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous research has demonstrated that the uterine microbiota can impact fertility and&#xD;
      embryo implantation. This information leads to the hypothesis that prophylactic antibiotic&#xD;
      and/or probiotic treatment may improve reproductive outcomes in women with unexplained&#xD;
      infertility/endometriosis who are seeking In Vitro Fertilization (IVF). No therapeutic&#xD;
      protocols to improve these outcomes currently exist. However, there are safe and easily&#xD;
      accessible medications and supplements that may be able to optimally modify the uterine&#xD;
      microbiota. Herein we are proposing a proof of concept pilot study of the feasibility, safety&#xD;
      and tolerability of administering oral probiotics, or oral probiotics in combination with&#xD;
      antibiotics, to women seeking IVF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of study enrollment</measure>
    <time_frame>Screening</time_frame>
    <description>Evaluated by number of eligible participants consenting to enrollment in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of retention of study participants</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Evaluated by number of study participants who complete, drop out or withdraw from the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants adhering to study protocol</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Evaluated as the percentage of study participants reporting daily administration of study interventions throughout the intervention period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of intervention-emergent adverse events</measure>
    <time_frame>Immediately after the intervention</time_frame>
    <description>Evaluated as the percentage of adverse events occurring in each intervention group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in implantation rate</measure>
    <time_frame>Endpoint of interventions to 4 weeks gestation (if applicable)</time_frame>
    <description>Evaluated by number of people with a positive beta hCG 2 weeks following frozen embryo transfer (FET), between intervention groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in clinical pregnancy rate</measure>
    <time_frame>Endpoint of interventions to 6 weeks gestation (if applicable)</time_frame>
    <description>Evaluated by number of people with a clinical pregnancy (gestational sac with fetal pole and cardiac activity seen on ultrasound at 6 weeks gestation), between intervention groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in ongoing pregnancy rate</measure>
    <time_frame>Endpoint of interventions to 12 weeks gestation (if applicable)</time_frame>
    <description>Evaluated by number of people with an ongoing pregnancy (gestational sac with fetal pole and cardiac activity seen on ultrasound at 12 weeks gestation), between intervention groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in uterine microbiota composition</measure>
    <time_frame>Baseline, immediately after interventions</time_frame>
    <description>Evaluated by 16S rRNA sequencing of the uterine microbiota at baseline versus on the day of FET, and compared between experimental groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum LPS</measure>
    <time_frame>Baseline, immediately after interventions</time_frame>
    <description>Evaluated by changes in LPS-binding protein (LPS) at baseline versus on the day of FET, and compared between intervention groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intestinal permeability</measure>
    <time_frame>Baseline, immediately after interventions</time_frame>
    <description>Evaluated by changes in untargeted peripheral blood metabolites at baseline versus on the day of FET, and compared between intervention groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral cytokines</measure>
    <time_frame>Baseline, immediately after interventions</time_frame>
    <description>Evaluated by changes in peripheral cytokines (TNF, IL-6, IL-8, IFNg - in pg/mL) at baseline versus on the day of FET, and compared between intervention groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary metabolites</measure>
    <time_frame>Baseline, immediately after interventions</time_frame>
    <description>Evaluated by changes untargeted urinary metabolites at baseline versus on the day of FET, and compared between intervention groups. Nontargeted metabolic phenotyping of &gt;100 urinary metabolites will be performed by multisegment injection capillary electrophoresis-mass spectrometry (MSI-CE-MS) as a high throughput platform to analyze metabolites. The fold change for each metabolite will be calculated between baseline vs. after interventions, and the fold changes will be compared between intervention groups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Unexplained Infertility</condition>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Probiotic + Antibiotic Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic + Antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic Placebo + Antibiotic Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SH-DS01 + Antibiotic Placebo</intervention_name>
    <description>Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.</description>
    <arm_group_label>Probiotic + Antibiotic Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH-DS01 + Metronidazole</intervention_name>
    <description>Participants will be instructed to take 2 capsules of SH-DS01 probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of SH-DS01 probiotic once daily (at lunch) and 1 capsule of 500mg metronidazole twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.</description>
    <arm_group_label>Probiotic + Antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic Placebo + Antibiotic Placebo</intervention_name>
    <description>Participants will be instructed to take 2 capsules of placebo for probiotic once daily (at lunch) from cycle day 1 to the day of ovulation/day of luteal progesterone initiation, followed by 2 capsules of placebo for probiotic once daily (at lunch) and 1 capsule of placebo for antibiotic twice daily (at breakfast and dinner) from the day of ovulation/day of luteal progesterone initiation to the day of frozen embryo transfer.</description>
    <arm_group_label>Probiotic Placebo + Antibiotic Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female aged 18-40 at the time of egg retrieval&#xD;
&#xD;
          2. Generally in good health (at physician's discretion)&#xD;
&#xD;
          3. Diagnosed with Unexplained Infertility&#xD;
&#xD;
          4. Diagnosed with or suspected of having endometriosis (at ONE Fertility physician's&#xD;
             discretion)&#xD;
&#xD;
          5. Normal uterine cavity as assessed by prior sonohysterogram&#xD;
&#xD;
          6. Planning to undergo Frozen Embryo Transfer with ≥1 frozen blastocyst ≥3BB (grade&#xD;
             Gardner) to transfer&#xD;
&#xD;
          7. Able to understand, comply and consent to protocol requirements and instructions&#xD;
&#xD;
          8. Able to attend scheduled study visits and complete required investigations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any known endometrial pathologies other than endometriosis&#xD;
&#xD;
          2. Polycystic ovary syndrome&#xD;
&#xD;
          3. Ovulatory dysfunction&#xD;
&#xD;
          4. Male factor infertility (Total Motile Sperm Count &lt;5M/mL)&#xD;
&#xD;
          5. Poorly controlled auto-immune disease and/or diabetes (at physician's discretion)&#xD;
&#xD;
          6. Is immune-compromised&#xD;
&#xD;
          7. Cockayne syndrome&#xD;
&#xD;
          8. Allergy to Metronidazole&#xD;
&#xD;
          9. Allergy to rice (bran and hull), pomegranate, Acacia gum, hypromellose, fermented&#xD;
             gellan gum, chlorophyllin, or sunflower oil&#xD;
&#xD;
         10. Known intolerance of Lactobacillus and/or Bifidobacterium-containing probiotics&#xD;
&#xD;
         11. Antibiotic use in the past month&#xD;
&#xD;
         12. Use of any of the following:&#xD;
&#xD;
               1. Oral probiotics&#xD;
&#xD;
               2. Alcohol&#xD;
&#xD;
               3. Anticoagulant therapies (Warfarin type)&#xD;
&#xD;
               4. Drugs containing alcohol&#xD;
&#xD;
               5. Busulfan&#xD;
&#xD;
               6. Cyclosporin&#xD;
&#xD;
               7. Disulfiram&#xD;
&#xD;
               8. 5-Fluoruracil&#xD;
&#xD;
               9. Lithium&#xD;
&#xD;
              10. Phenytoin or Phenobarbital&#xD;
&#xD;
              11. Vecuronium&#xD;
&#xD;
              12. Proton pump inhibitors&#xD;
&#xD;
              13. Histamine H2-receptor antagonists&#xD;
&#xD;
         13. Currently experiencing nausea, fever, vomiting, bloody diarrhea or severe abdominal&#xD;
             pain&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jocelyn Wessels, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jocelyn Wessels, PhD</last_name>
    <phone>1-905-525-9140</phone>
    <phone_ext>27964</phone_ext>
    <email>wessels@mcmaster.ca</email>
  </overall_contact>
  <reference>
    <citation>Eckert LO, Moore DE, Patton DL, Agnew KJ, Eschenbach DA. Relationship of vaginal bacteria and inflammation with conception and early pregnancy loss following in-vitro fertilization. Infect Dis Obstet Gynecol. 2003;11(1):11-7.</citation>
    <PMID>12839628</PMID>
  </reference>
  <reference>
    <citation>Selman H, Mariani M, Barnocchi N, Mencacci A, Bistoni F, Arena S, Pizzasegale S, Brusco GF, Angelini A. Examination of bacterial contamination at the time of embryo transfer, and its impact on the IVF/pregnancy outcome. J Assist Reprod Genet. 2007 Sep;24(9):395-9. Epub 2007 Jul 17.</citation>
    <PMID>17636439</PMID>
  </reference>
  <reference>
    <citation>Moreno I, Codoñer FM, Vilella F, Valbuena D, Martinez-Blanch JF, Jimenez-Almazán J, Alonso R, Alamá P, Remohí J, Pellicer A, Ramon D, Simon C. Evidence that the endometrial microbiota has an effect on implantation success or failure. Am J Obstet Gynecol. 2016 Dec;215(6):684-703. doi: 10.1016/j.ajog.2016.09.075. Epub 2016 Oct 4.</citation>
    <PMID>27717732</PMID>
  </reference>
  <reference>
    <citation>Kyono K, Hashimoto T, Nagai Y, Sakuraba Y. Analysis of endometrial microbiota by 16S ribosomal RNA gene sequencing among infertile patients: a single-center pilot study. Reprod Med Biol. 2018 May 6;17(3):297-306. doi: 10.1002/rmb2.12105. eCollection 2018 Jul.</citation>
    <PMID>30013432</PMID>
  </reference>
  <reference>
    <citation>Fanchin R, Harmas A, Benaoudia F, Lundkvist U, Olivennes F, Frydman R. Microbial flora of the cervix assessed at the time of embryo transfer adversely affects in vitro fertilization outcome. Fertil Steril. 1998 Nov;70(5):866-70.</citation>
    <PMID>9806568</PMID>
  </reference>
  <reference>
    <citation>Egbase PE, Udo EE, Al-Sharhan M, Grudzinskas JG. Prophylactic antibiotics and endocervical microbial inoculation of the endometrium at embryo transfer. Lancet. 1999 Aug 21;354(9179):651-2.</citation>
    <PMID>10466674</PMID>
  </reference>
  <reference>
    <citation>Moore DE, Soules MR, Klein NA, Fujimoto VY, Agnew KJ, Eschenbach DA. Bacteria in the transfer catheter tip influence the live-birth rate after in vitro fertilization. Fertil Steril. 2000 Dec;74(6):1118-24.</citation>
    <PMID>11119737</PMID>
  </reference>
  <reference>
    <citation>Brook N, Khalaf Y, Coomarasamy A, Edgeworth J, Braude P. A randomized controlled trial of prophylactic antibiotics (co-amoxiclav) prior to embryo transfer. Hum Reprod. 2006 Nov;21(11):2911-5. Epub 2006 Jul 10.</citation>
    <PMID>16832124</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McMaster University</investigator_affiliation>
    <investigator_full_name>Jocelyn Wessels</investigator_full_name>
    <investigator_title>Postdoctoral Fellow</investigator_title>
  </responsible_party>
  <keyword>Uterine microbiota</keyword>
  <keyword>Endometrial microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

